Insulin pump approval breathes life into Novo Nordisk and Ypsomed collaboration

28 June 2016

The European Medicines Agency has granted marketing approval to the mylife YpsoPump for use with the prefilled pump cartridge NovoRapid PumpCart.

This approval marks a key milestone in the collaboration between Danish diabetes giant Novo Nordisk (NOV: N) and Switzerland-based Ypsomed Holding AG (YPSN: SIX Swiss Ex).

Ypsomed’s YpsoPump is an insulin pump which is fully compatible with the Novo Nordisk’s NovoRapid PumpCart, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK